A light-activated switch wakes up dormant cancer

Introduction: when cancer cells pretend to sleep

A problem the public rarely hears about

Researchers at ETH Zurich have developed a system capable of waking up cancer cells stuck in a dormant state, a survival mechanism that lets them dodge the destructive effect of standard treatments. This discovery, published on May 21, 2026 in the scientific journal PNAS, opens up a novel avenue against certain forms of lung cancer, with potential applications for breast cancer and prostate cancer.

The principle may come as a surprise: rather than attacking tumor cells head-on, the scientists chose to "wake them up" from their protective sleep, a necessary first step so existing treatments can finally reach them effectively.

Why some cancer cells resist treatment

In certain forms of lung cancer, tumor cells can enter a state where they divide very little, almost as if hibernating. This behavior is triggered by stress hormones recognized by glucocorticoid receptors present inside cancer cells. Once that signal is received, the cell dramatically slows its activity, making it largely invisible and unreachable for most chemotherapies, which are designed to target actively dividing cells.

The molecular mechanism behind this breakthrough

A natural recycling system cleverly redirected

To wake up these dormant cells, the team led by Professor Katharina Gapp, a specialist in epigenetics and neuroendocrinology, redirected a natural recycling system already present in the human body. This system normally detects defective proteins and marks them for elimination, attaching a small molecule that acts like a waste tag, before the protein is degraded by the cell itself.

The researchers modified this natural process to specifically target the glucocorticoid receptors found on tumor cells, rather than random defective proteins. It's an elegant way to turn an existing biological mechanism against the disease itself.

Three parts for a molecular switch

The switch they built has three distinct parts: a subunit that latches directly onto the target receptor, a flexible linker piece at the center of the device, and a second subunit that attaches to the enzyme responsible for placing the degradation tag. It's this flexible central piece, developed by the team of Professor Erick Carreira, a specialist in organic synthesis, that represents the true technical innovation of this research.

Light as a precision switch

A wavelength-controlled flip

The heart of the innovation lies in how the flexible linker piece behaves around light. In normal light, this piece stays stretched out, placing the enzyme exactly the right distance from the receptor to allow tagging and degradation of the latter. But under light of a specific wavelength, the piece bends, pulling the enzyme away from the receptor and preventing the degradation tag from attaching, blocking the entire process.

This light-controlled reversibility lets researchers switch the system's effect on or off at will, depending on exactly where in the patient's body they want it to act.

Protecting healthy tissue with a targeted beam

In practice, the system would be injected directly into the tumor, then a light beam would be used to specifically deactivate any switches that migrated out of the tumor zone into surrounding healthy tissue. According to Robin Scheuplein, co-first author of the study and a doctoral researcher in Katharina Gapp's group, this approach strictly confines the treatment's activity to the heart of the tumor, preserving neighboring tissue and significantly reducing side effects.

Why this level of precision is essential

Receptors found throughout the body

It's worth understanding why such a targeted approach was necessary: every cell in the human body carries glucocorticoid receptors, essential for vital functions like reducing inflammation and keeping the immune system running properly. Eliminating these receptors indiscriminately throughout the body would cause potentially disastrous side effects for the patient's overall health.

It's precisely this biological constraint that pushed the Zurich team to develop a system able to selectively neutralize its own effect outside the tumor zone, rather than searching for a molecule that naturally targets cancer cells alone, a far harder chemical task to pull off.

A technology built on already-established medical foundations

According to Robin Scheuplein, this system relies on already-existing medical technology, which, in his own words, offers "a realistic outlook for localized therapies" rather than a mere lab curiosity with no foreseeable clinical application in the medium term.

The results obtained in the lab

Rapid degradation observed in lung cells

In lung cancer cell cultures in the lab, researchers observed exactly the biological effect they were after: the active substance triggered rapid degradation of the glucocorticoid receptors present on the tested tumor cells. A detailed analysis of the cells' genetic activity then confirmed they were indeed emerging from their dormant state after this treatment.

This result, though still limited to the cell-culture stage, constitutes an encouraging proof of concept for the further development of this therapeutic approach, validating the researchers' original hypothesis about the cell dormancy mechanism.

Scientific caution the authors themselves embrace

Robin Scheuplein himself acknowledges the current limits of this work, noting that these results still need to be "verified in living organisms," a crucial step separating any lab discovery from a real clinical application in human patients.

The technical hurdles still to clear

Light only penetrates a few millimeters

One of the major challenges of this technology remains the limited reach of light in biological tissue, which only penetrates a few millimeters before fading out. The light source therefore needs to be positioned right at the edges of the tumor to effectively establish this protective optical barrier around the treated zone.

For lung cancer, researchers are considering using an endoscope to deliver light directly to the tumor site, a technical solution already commonly used in other pulmonary medical procedures.

Toward more penetrating wavelengths for deeper tumors

For tumors located deeper in the body, out of reach of a standard endoscope, the research team wants to develop versions of the switch sensitive to longer wavelengths, particularly in the near-infrared range, a light spectrum that penetrates human tissue more deeply and gently than the visible light currently used.

Applications that could go beyond lung cancer alone

Breast cancer and prostate cancer in the crosshairs

Beyond lung cancer, researchers are considering adapting this modular system to target other receptors involved in different types of cancer. The estrogen receptor, involved in certain hormone-dependent breast cancers, and the androgen receptor, present in advanced prostate cancers, are among the targets being considered for future adaptations of this technology.

According to Robin Scheuplein, the team developed "a modular system" that can also be used to deactivate other receptors, considerably widening the potential application of this discovery beyond the original scope of the research.

A tool already useful for basic research

Even before any clinical application, this system is already usable in basic research to help scientists better understand the complex signaling pathways involved in cancer biology, a use that could accelerate other parallel discoveries in the field of molecular oncology.

A multidisciplinary scientific collaboration behind the breakthrough

Chemists and biologists brought together around one goal

This breakthrough wouldn't have been possible without close collaboration between several research groups at ETH Zurich, blending expertise in organic chemistry, molecular biology, and neuroendocrinology. Professor Erick Carreira's team produced several versions of the flexible linker piece before identifying the two variants with exactly the photosensitive properties the biologists in Katharina Gapp's group were looking for.

This kind of cross-disciplinary collaboration between synthetic chemists and cancer biologists illustrates a deeper trend in contemporary medical research, where the most promising breakthroughs increasingly emerge at the intersection of several scientific disciplines rather than from a single isolated field of expertise.

A publication detailing rigorous methodology

The scientific paper, published in the journal PNAS on May 21, 2026 under the title "Light-controlled disruption of cancer cell dormancy via photoswitchable stress hormone receptor degraders," lists about a dozen co-authors, reflecting the scale of experimental work needed to validate every step of this complex mechanism, from initial chemical synthesis to cell-culture testing.

Conclusion: measured hope worth watching closely

A promising step, not an immediate cure

This discovery from ETH Zurich perfectly illustrates what oncology research does best: turning a fine-grained understanding of cancer's biological mechanisms into concrete therapeutic leads, without giving in to the temptation of promising an immediate miracle cure. The road between these lab results and an available treatment for patients remains long, punctuated by essential validation steps in living organisms, and then possible clinical trials.

But the scientific logic behind this approach, waking dormant cells to make them vulnerable again, opens an original therapeutic path that could, eventually, add to the existing arsenal against certain cancers particularly resistant to current treatments.

What patients and their families should take from this today

For patients facing lung cancer today, it's important to understand that this technology is not yet clinically available and won't be for several years, until the necessary validation steps are completed. It nonetheless represents an encouraging example of how basic research keeps opening new paths against a disease that remains one of the world's leading causes of death.

By Maxime Marquette, columnist

Columnist's transparency note

This investigation draws on the research release published by ETH Zurich and on the corresponding scientific paper published in the journal PNAS on May 21, 2026, cited as sources below. The quotes attributed to Robin Scheuplein come directly from ETH Zurich's institutional release. This piece popularizes lab research results that have not yet been tested in living organisms or in humans, a point the authors themselves explicitly note. No promise of a short-term available treatment is made in this article.

Sources

Primary sources

ETH Zürich, research release on the photosensitive switch — June 15, 2026

PNAS, original scientific publication — May 21, 2026

Secondary sources

ScienceDaily, coverage of the ETH Zurich discovery — June 2026

StudyFinds, explainer on the cancer kill switch — June 2026

ETH Zürich, science news portal — accessed July 2026

PNAS, Proceedings of the National Academy of Sciences, journal portal — accessed July 2026